Innovent Biologics, WuXi Biologics, and Danuo Pharmaceuticals basically didn't move today — Hong Kong stock innovative drugs and CXO are just this kind of quiet sideways movement 🤔 Innovative drugs have been waiting for the medical insurance negotiation and key clinical data, while CXOs are waiting for visibility into overseas orders. On days without new catalysts, capital is also too lazy to move. Valuation recovery for Hong Kong-listed pharmaceutical stocks often requires a clear data or policy catalyst to ignite it. Buying the dip during the sideways period can easily wear down one's patience — do you think the turning point this time will come first from the medical insurance negotiation or from a recovery in CXO orders?
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
